Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

For decades, aging has looked like a one-way street, a slow accumulation of damage written into our cells. Now a wave of ...

Scientists discover how aging alters the function of cells, called mesenchymal drift, and manage to reverse this process.

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Chemotherapy’s gut damage turns out to have a surprising upside. By changing nutrient availability in the intestine, it ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

Ameya Dravid is a postdoctoral researcher in Ankur Singh’s lab at Georgia Tech. In this postdoc portrait article, he ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

The tumor microenvironment (TME) is a metabolically dynamic niche where cancer cells and immune cells interact to influence tumor progression and immune ...